LEXX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	123 825
Average Volume	496 879
Market Cap	27.85M
EPS	$0 ( 2024-04-12 )
Next earnings date	( $-0.130 ) 2024-07-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.68
ATR14	$0.0190 (0.84%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Cabatuan Nelson	Sell	200 000	Stock Options
2023-10-26	Carle Vanessa	Buy	12 500	Stock Options
2023-10-26	Docherty John Martin	Buy	30 000	Stock Options
2023-10-26	Bunka Christopher	Buy	30 000	Stock Options
2023-07-25	Baxter Nicholas W	Buy	5 000	Stock Options

INSIDER POWER
-24.05
Last 99 transactions
Buy: 4 974 810 \| Sell: 2 651 735

Volume Correlation

Long: -0.11 (neutral)

Short: 0.86 (strong)

Signal:(46.921) Same movement expected

Lexaria Bioscience Corp. Correlation

10 Most Positive Correlations
RMRM	0.854
AKU	0.828
GAINL	0.828
LPLA	0.824
UNB	0.822
LMST	0.821
OCFC	0.809
SFBC	0.807
EFSC	0.807
LBAI	0.806

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lexaria Bioscience Corp. Correlation - Currency/Commodity

-0.32
( neutral )

-0.48
( neutral )

0.00
( neutral )

-0.64
( weak negative )

0.28
( neutral )

-0.42
( neutral )

Lexaria Bioscience Corp. Financials

Annual	2023
Revenue:	$226 208
Gross Profit:	$194 708 (86.07 %)
EPS:	$-1.010

Q4	2023
Revenue:	$-3 433.00
Gross Profit:	$-6 866.00 (200.00 %)
EPS:	$-0.190

Q3	2023
Revenue:	$93 150.00
Gross Profit:	$80 403.00 (86.32 %)
EPS:	$-0.370

Q2	2023
Revenue:	$35 015.00
Gross Profit:	$32 057.00 (91.55 %)
EPS:	$-0.220

Financial Reports:

No articles found.

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.